Select Medical Holdings Corporation

DB:S24 Stock Report

Market Cap: €4.9b

Select Medical Holdings Valuation

Is S24 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of S24 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: S24 (€37.4) is trading below our estimate of fair value (€158.18)

Significantly Below Fair Value: S24 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for S24?

Key metric: As S24 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for S24. This is calculated by dividing S24's market cap by their current earnings.
What is S24's PE Ratio?
PE Ratio19.3x
EarningsUS$265.80m
Market CapUS$5.12b

Price to Earnings Ratio vs Peers

How does S24's PE Ratio compare to its peers?

The above table shows the PE ratio for S24 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.8x
RHK RHÖN-KLINIKUM
18.6x7.5%€836.7m
M12 M1 Kliniken
18.3x17.5%€307.1m
LIK LIMES Schlosskliniken
23.3xn/a€99.7m
FME Fresenius Medical Care
18.8x19.3%€12.4b
S24 Select Medical Holdings
19.3x11.9%€5.1b

Price-To-Earnings vs Peers: S24 is good value based on its Price-To-Earnings Ratio (19.3x) compared to the peer average (19.8x).

Price to Earnings Ratio vs Industry

How does S24's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
S24 19.3xIndustry Avg. 18.7xNo. of Companies10PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: S24 is expensive based on its Price-To-Earnings Ratio (19.3x) compared to the European Healthcare industry average (18.7x).

Price to Earnings Ratio vs Fair Ratio

What is S24's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

S24 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.3x
Fair PE Ratio24x

Price-To-Earnings vs Fair Ratio: S24 is good value based on its Price-To-Earnings Ratio (19.3x) compared to the estimated Fair Price-To-Earnings Ratio (24x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst S24 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€37.40
€42.87
+14.6%
8.3%€47.21€37.77n/a5
Nov ’25€30.20
€40.05
+32.6%
11.3%€46.14€34.14n/a5
Oct ’25€30.80
€38.91
+26.3%
11.3%€44.83€33.17n/a5
Sep ’25€32.20
€38.91
+20.8%
11.3%€44.83€33.17n/a5
Aug ’25€36.60
€37.32
+2.0%
14.1%€44.05€31.20n/a3
Jul ’25€32.40
€35.87
+10.7%
7.7%€38.63€31.27n/a4
Jun ’25€31.40
€35.87
+14.2%
7.7%€38.63€31.27n/a4
May ’25€26.00
€32.74
+25.9%
9.6%€36.58€28.35n/a5
Apr ’25€27.60
€32.74
+18.6%
9.6%€36.58€28.35n/a5
Mar ’25€24.80
€32.53
+31.2%
11.9%€36.86€26.27n/a5
Feb ’25€24.00
€30.44
+26.8%
15.3%€36.56€26.05n/a5
Jan ’25€21.60
€29.59
+37.0%
15.4%€35.83€23.89n/a5
Dec ’24€20.60
€29.59
+43.6%
15.4%€35.83€23.89n/a5
Nov ’24€21.40
€35.10
+64.0%
3.0%€36.50€33.69€30.204
Oct ’24€24.20
€35.10
+45.0%
3.0%€36.50€33.69€30.804
Sep ’24€26.80
€33.08
+23.4%
6.6%€35.44€29.08€32.205
Aug ’24€27.00
€32.17
+19.1%
9.9%€35.04€26.06€36.605
Jul ’24€29.40
€32.54
+10.7%
9.9%€35.45€26.36€32.405
Jun ’24€25.20
€32.54
+29.1%
9.9%€35.45€26.36€31.405
May ’24€27.00
€31.28
+15.8%
10.5%€36.74€27.32€26.005
Apr ’24€23.20
€31.28
+34.8%
10.5%€36.74€27.32€27.605
Mar ’24€25.20
€31.30
+24.2%
10.5%€36.77€27.34€24.805
Feb ’24€26.60
€29.81
+12.1%
15.7%€36.33€22.36€24.005
Jan ’24€23.20
€30.67
+32.2%
16.6%€37.85€23.29€21.605
Dec ’23€23.60
€30.67
+29.9%
16.6%€37.85€23.29€20.605
Nov ’23€25.80
€35.52
+37.7%
16.8%€44.15€27.09€21.405

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-8.8%

1Y

-37.3%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-5.5%

1Y

18.9%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%